French pharmaceutical startup Pharnext is leveraging AI and pleiotropy to develop new drug combinations and repurpose existing therapies, Fortune reported March 19.

A remote monitoring protocol for heart failure patients with implantable electronic devices helped more of them stay out of the hospital over a one-year period than standard in-person visits, researchers reported at EHRA 2019.

Richard Kovacs, MD, officially began his one-year stint as the president of the American College of Cardiology on March 18. The occasion was marked during a convocation ceremony on the final day of the ACC’s scientific sessions in New Orleans.

A multitude of recent studies and success stories suggest artificial intelligence is on its way to topping doctors in accurately diagnosing diseases from asthma to breast cancer—seemingly a step in the right direction. But does the hype surrounding AI’s victories eclipse its shortcomings?

The American College of Cardiology (ACC) and the American Board of Internal Medicine (ABIM) announced on March 15 an alternative option for cardiologists to maintain their board certification. The Collaborative Maintenance Pathway (CMP) will feature an annual performance assessment, each covering about 20 percent of the field of cardiovascular disease, so the entire span of general cardiology can be covered in five years.

Artificial intelligence shows great promise in recognizing patterns, liberating physicians from keyboards and predicting outcomes, but where does it fall short? Medical guru Eric Topol does a deep dive into those topics and many more in his new book, Deep Medicine.

A deep neural network crafted by research specialists at Dartmouth’s Norris Cotton Cancer Center identified different types of lung adenocarcinoma as well as practicing pathologists in a recent study, according to work published March 4 in Scientific Reports.

A 14-week health technology “sprint” sponsored by the U.S. Census Bureau and coordinated by HHS has produced an AI tool that developers claim could revolutionize the way researchers match cancer patients with clinical trials.